Acticor Biotech's GREEN Study Continues After Positive Interim Analysis

Acticor Biotech's GREEN Study Advances

Acticor Biotech, a clinical-stage biotechnology company, has announced positive results from the interim futility analysis of its ongoing GREEN study. The study is evaluating glenzocimab, a novel treatment for acute ischemic stroke, in combination with standard of care thrombolysis and/or thrombectomy 1

1

Interim Analysis Outcome

The independent Data Monitoring Committee (DMC) has recommended the continuation of the GREEN study without any modifications to the protocol. This decision was based on their review of the interim futility analysis, which examined data from the first 100 patients enrolled in the trial 2

2

Significance of the Results

The positive outcome of the futility analysis is a crucial milestone for Acticor Biotech. It indicates that glenzocimab shows promise as a potential treatment for acute ischemic stroke, warranting further investigation in the ongoing phase 2/3 study 1

1

About the GREEN Study

The GREEN study is a randomized, double-blind, multicenter, placebo-controlled, parallel-group phase 2/3 study. It aims to evaluate the efficacy and safety of glenzocimab in combination with standard of care (thrombolysis, thrombectomy, or both) for acute ischemic stroke 2

2

Glenzocimab: A Promising Treatment

Glenzocimab is a humanized monoclonal antibody fragment that inhibits platelet glycoprotein VI (GPVI). It is designed to be used in emergency situations as a first-line treatment for acute ischemic stroke, in combination with reperfusion treatments such as thrombolysis and/or thrombectomy 1

1

Related Stories

Acticor Biotech Reports on Liquidity Contract with Kepler Cheuvreux

Actuate Therapeutics to Showcase AI-Driven Drug Development in Lantern Pharma Webinar

Transgene and BioInvent's BT-001 Shows Promise in Solid Tumor Treatment

OPM Reports Positive Phase 1 Results for OPM-101 in Healthy Volunteers

Next Steps

With the positive outcome of the interim analysis, Acticor Biotech will continue the GREEN study as planned. The company aims to complete patient enrollment by the end of 2023 and expects to have the full results of the study available in Q2 2024 2

2

Management's Perspective

Gilles Avenard, CEO of Acticor Biotech, expressed satisfaction with the interim analysis results. He emphasized the importance of this milestone in the development of glenzocimab and reiterated the company's commitment to bringing innovative treatments to stroke patients 1

1